Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Atabecestat in Healthy Japanese Males
NCT02180269Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs), Maximum Plasma Concentration and 3 more. Started Jun 2014; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02180269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180269.